IVD試薬市場は、2024年の604億5000万ドルから2029年までに874億1000万ドルに成長し、予測期間中に7.7%のCAGRで成長すると予想されます。市場の主要なプレーヤーには、Danaher Corporation(米国)、F. Hoffmann-La Roche Ltd(スイス)、Abbott(米国)、Siemens Healthineers AG(ドイツ)、Thermo Fisher Scientific Inc.(米国)、Illumina、Inc.(米国)、BioMerieux(フランス)、BD(米国)、Hologic、Inc.(米国)、Bio-Rad Laboratories、Inc.(米国)、シスメックス（株）(日本)、QIAGEN N.V.(オランダ)、Agilent Technologies、Inc.(米国)、Revvity(米国)、DiaSorin S.p.A.(イタリア)、Grifols、S.A.(スペイン)、 Werfen, S.A. (スペイン)、QuidelOrtho Corporation (米国)、Chembio Diagnostics, Inc. (米国)、Surmodics, Inc. (米国)、Merck KGaA (ドイツ)、MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.(株式会社医学生物学研究所) (日本)、Canvax (スペイン)、Prestige Diagnostics (米国)、Adaltis S.r.l. (イタリア)、Randox Laboratories Ltd. (英国)
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 MARKET RECONCILIATION
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Key data from primary sources
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
2.2.1.2 Approach 2: Presentations of companies and primary interviews
2.2.1.3 Approach 3: Primary interviews
2.2.1.4 Growth forecast
2.2.1.5 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.4.1 STUDY-RELATED ASSUMPTIONS
2.4.2 PARAMETRIC ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 IVD REAGENTS MARKET OVERVIEW
4.2 ASIA PACIFIC: IVD REAGENTS MARKET, BY COUNTRY
4.3 NORTH AMERICA: IVD REAGENTS MARKET, BY TEST TYPE AND COUNTRY
4.4 IVD REAGENTS MARKET, BY COUNTRY
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing geriatric population
5.2.1.2 Gradual shift toward point-of-care testing and automated analyzers
5.2.1.3 Rise in early diagnosis and personalized medicine
5.2.1.4 Increasing adoption of third-party quality controls
5.2.1.5 Growing biotechnology and biopharmaceutical industries
5.2.1.6 Increasing funding for R&D activities
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.2.2 Stringent regulatory requirements
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing development of biomarkers
5.2.3.2 Rising significance of companion diagnostics
5.2.3.3 Market growth opportunities in emerging economies
5.2.3.4 Growing trend of digitalization
5.2.4 CHALLENGES
5.2.4.1 Operational challenges in clinical process
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
5.4.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION
5.4.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.2 ADJACENT TECHNOLOGIES
5.9.2.1 Multiplexed point-of-care testing
5.9.2.2 Nucleic acid lateral flow immunoassay
5.9.2.3 DNA-based detection
5.9.2.4 Immunodiagnostics
5.9.2.5 Dual path technology
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA
5.11.2 EXPORT DATA
5.12 KEY CONFERENCES AND EVENTS, 2024-2025
5.13 PORTER'S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTES
5.13.3 BARGAINING POWER OF SUPPLIERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 REGULATORY ANALYSIS
5.14.1 REGULATORY LANDSCAPE
5.14.1.1 North America
5.14.1.1.1 US
5.14.1.1.2 Canada
5.14.1.2 Europe
5.14.1.3 Asia Pacific
5.14.1.3.1 China
5.14.1.3.2 Japan
5.14.1.3.3 India
5.14.1.4 Latin America
5.14.1.4.1 Brazil
5.14.1.5 Middle East
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.1 North America
5.14.2.2 Europe
5.14.2.3 Asia Pacific
5.14.2.4 Latin America
5.14.2.5 Middle East & Africa
5.14.2.6 GCC Countries
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA
5.16 IMPACT OF AI/GENERATIVE AI ON IVD REAGENTS MARKET
5.16.1 INTRODUCTION
5.16.2 MARKET POTENTIAL FOR IVD REAGENTS
5.16.3 AI USE CASES
5.16.4 KEY COMPANIES IMPLEMENTING AI
5.16.5 FUTURE OF GENERATIVE AI ON IVD REAGENTS
6 IVD REAGENTS MARKET, BY TYPE
6.1 INTRODUCTION
6.2 ANTIBODIES
6.2.1 MONOCLONAL ANTIBODIES
6.2.1.1 Increasing incidence of cancer to stimulate growth
6.2.2 POLYCLONAL ANTIBODIES
6.2.2.1 Rising prevalence of infectious diseases and autoimmune disorders to support growth
6.3 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES
6.3.1 INCREASING FOCUS ON ADVANCED PRECISION MEDICINE TO ENCOURAGE GROWTH
6.4 OLIGONUCLEOTIDES
6.4.1 GROWING INCLINATION TOWARD MOLECULAR DIAGNOSTICS TO DRIVE MARKET
6.5 NUCLEIC ACID PROBES
6.5.1 NEED FOR EARLY DISEASE DETECTION AND MONITORING LOW-ABUNDANCE BIOMARKERS TO AID GROWTH
6.6 OTHER IVD REAGENTS
7 IVD REAGENTS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 IMMUNOASSAYS
7.2.1 RISING TREND OF AUTOMATION TO PROMOTE GROWTH
7.3 CLINICAL CHEMISTRY
7.3.1 RISING PREVALENCE OF DIABETES TO BOOST SEGMENT
7.4 MOLECULAR DIAGNOSTICS
7.4.1 GROWING DEMAND FOR BLOOD SCREENING AND POINT-OF-CARE TESTING TO FUEL MARKET
7.5 HEMATOLOGY
7.5.1 INCREASING FOCUS ON STEM CELL RESEARCH TO SPEED UP GROWTH
7.6 MICROBIOLOGY
7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET
7.7 COAGULATION & HEMOSTASIS
7.7.1 GROWING USE OF ANTICOAGULATION THERAPY TO PROPEL MARKET
7.8 URINALYSIS
7.8.1 RISING PREVALENCE OF KIDNEY DISEASES TO SUPPORT MARKET GROWTH
7.9 CHROMATOGRAPHY & MASS SPECTROMETRY
7.9.1 INCREASING APPLICATIONS IN DISEASE SCREENING, FORENSIC ANALYSIS, AND DRUG THERAPY TO BOOST MARKET
7.10 IMMUNOHISTOCHEMISTRY
7.10.1 GROWING NUMBER OF LABORATORY TESTS FOR CANCER DIAGNOSIS TO DRIVE MARKET
8 IVD REAGENTS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 INFECTIOUS DISEASES
8.2.1 INCREASING PRODUCT LAUNCHES AND APPROVALS TO BOOST MARKET
8.3 ONCOLOGICAL APPLICATIONS
8.3.1 GROWING EMPHASIS ON EARLY DIAGNOSIS AND QUALITY TREATMENT TO FUEL MARKET
8.4 ENDOCRINOLOGICAL APPLICATIONS
8.4.1 RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO SUSTAIN GROWTH
8.5 CARDIOLOGICAL APPLICATIONS
8.5.1 CHANGING LIFESTYLES IN DEVELOPED AND DEVELOPING COUNTRIES TO PROPEL MARKET
8.6 BLOOD SCREENING
8.6.1 RISING ADOPTION OF AUTOMATED DIAGNOSTIC INSTRUMENTS TO FACILITATE GROWTH
8.7 GENETIC TESTING
8.7.1 INCREASING ADOPTION OF GENETIC TESTING TO DIAGNOSE RARE AND FATAL DISEASES TO SUSTAIN GROWTH
8.8 AUTOIMMUNE DISEASES
8.8.1 GROWING ADVANCEMENTS IN LABORATORY TECHNOLOGY, REAGENTS, AND ALTERNATIVE ASSAY METHODOLOGIES TO DRIVE MARKET
8.9 ALLERGY DIAGNOSTICS
8.9.1 GROWING FOCUS ON ALLERGY THERAPY AND PREVENTION TO ACCELERATE GROWTH
8.10 DRUG MONITORING & TESTING
8.10.1 GROWING IMPLEMENTATION OF DRUGS-OF-ABUSE TESTING TO DRIVE MARKET
8.11 OTHER APPLICATIONS
9 IVD REAGENTS MARKET, BY TEST TYPE
9.1 INTRODUCTION
9.2 LABORATORY TESTS
9.2.1 INCREASING NEED FOR AUTOMATION TO EXPEDITE GROWTH
9.3 POINT-OF-CARE TESTS
9.3.1 NEED TO CLOSELY MONITOR PATIENT CONDITIONS TO AUGMENT GROWTH
10 IVD REAGENTS MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS & CLINICS
10.2.1 INCREASING SPECIALTY DIAGNOSTIC TESTS TO ACCELERATE GROWTH
10.3 CLINICAL LABORATORIES
10.3.1 LARGE REFERENCE LABORATORIES
10.3.1.1 Need for specialized testing capabilities and minimal turnaround time to boost market
10.3.2 SMALL & MEDIUM-SIZED LABORATORIES
10.3.2.1 Growing adoption of automated and semi-automated instruments to support growth
10.4 BLOOD BANKS
10.4.1 GROWING NUMBER OF TRAUMA CASES AND AVAILABILITY OF SOPHISTICATED SURGICAL PROCEDURES TO FUEL MARKET
10.5 HOME CARE SETTINGS
10.5.1 GROWING PREFERENCE FOR AT-HOME TESTING KITS TO DRIVE MARKET
10.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.6.1 INCREASING RESEARCH & DEVELOPMENT EFFORTS TO CONTRIBUTE TO GROWTH
10.7 ACADEMIC INSTITUTES
10.7.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO FAVOR GROWTH
10.8 OTHER END USERS
11 IVD REAGENTS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Established reimbursement framework to drive market
11.2.3 CANADA
11.2.3.1 Rising incidence of chronic and infectious lifestyle diseases to propel market
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Increasing investments in clinical diagnostics research to drive market
11.3.3 UK
11.3.3.1 Rising adoption of genome-based testing to promote growth
11.3.4 FRANCE
11.3.4.1 High healthcare expenditure and rising investments in genomic medicine to boost market
11.3.5 ITALY
11.3.5.1 Growing geriatric population and subsequent rise in chronic conditions to support market growth
11.3.6 SPAIN
11.3.6.1 Rising adoption of immunoassay reagents to drive market
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 JAPAN
11.4.2.1 Rise in social health insurance programs to encourage growth
11.4.3 CHINA
11.4.3.1 Growing focus on preventive care to boost demand
11.4.4 INDIA
11.4.4.1 Rising prevalence of chronic diseases to fuel market
11.4.5 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Rising prevalence of diabetes to stimulate growth
11.5.3 MEXICO
11.5.3.1 Growing establishment of clinical laboratories to boost market
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING FOCUS ON IMMUNOLOGY AND PRENATAL & CANCER TESTING TO DRIVE MARKET
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.7 GCC COUNTRIES
11.7.1 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
11.7.2 KINGDOM OF SAUDI ARABIA
11.7.2.1 Rising healthcare expenditure to promote growth
11.7.3 UNITED ARAB EMIRATES
11.7.3.1 Increasing development of advanced healthcare infrastructure to expedite growth
11.7.4 OTHER GCC COUNTRIES
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS MARKET, 2021-2023
12.3 REVENUE ANALYSIS, 2021-2023
12.4 MARKET SHARE ANALYSIS, 2023
12.5 COMPANY VALUATION AND FINANCIAL METRICS
12.6 BRAND/PRODUCT COMPARISON
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.7.5.1 Company footprint
12.7.5.2 Technology footprint
12.7.5.3 Application footprint
12.7.5.4 Test type footprint
12.7.5.5 Region footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.8.5.1 Detailed list of key startups/SMEs
12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES AND APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS
12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 DANAHER CORPORATION
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Deals
13.1.1.3.2 Expansions
13.1.1.3.3 Other developments
13.1.1.4 MnM view
13.1.1.4.1 Right to win
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 F. HOFFMANN-LA ROCHE LTD.
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Deals
13.1.2.4 MnM view
13.1.2.4.1 Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 ABBOTT
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Deals
13.1.3.4 MnM view
13.1.3.4.1 Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 SIEMENS HEALTHINEERS AG
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Deals
13.1.4.4 MnM view
13.1.4.4.1 Right to win
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses and competitive threats
13.1.5 THERMO FISHER SCIENTIFIC INC.
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Deals
13.1.5.3.2 Expansions
13.1.5.4 MnM view
13.1.5.4.1 Right to win
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses and competitive threats
13.1.6 ILLUMINA, INC.
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Deals
13.1.7 BIOMERIEUX
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Deals
13.1.8 BD
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Deals
13.1.9 HOLOGIC, INC.
13.1.9.1 Business overview
13.1.9.2 Products offered
13.1.9.3 Recent developments
13.1.9.3.1 Product launches and approvals
13.1.9.3.2 Deals
13.1.10 BIO-RAD LABORATORIES, INC.
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.10.3 Recent developments
13.1.10.3.1 Deals
13.1.11 SYSMEX CORPORATION
13.1.11.1 Business overview
13.1.11.2 Products offered
13.1.11.3 Recent developments
13.1.11.3.1 Product launches and approvals
13.1.11.3.2 Deals
13.1.11.3.3 Expansions
13.1.12 QIAGEN N.V.
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.12.3 Recent developments
13.1.12.3.1 Deals
13.1.13 AGILENT TECHNOLOGIES, INC.
13.1.13.1 Business overview
13.1.13.2 Products offered
13.1.13.3 Recent developments
13.1.13.3.1 Deals
13.1.13.3.2 Expansions
13.1.14 REVVITY
13.1.14.1 Business overview
13.1.14.2 Products offered
13.1.14.3 Recent developments
13.1.14.3.1 Deals
13.1.14.3.2 Other developments
13.1.15 DIASORIN S.P.A.
13.1.15.1 Business overview
13.1.15.2 Products offered
13.1.15.3 Recent developments
13.1.15.3.1 Deals
13.1.16 GRIFOLS, S.A.
13.1.16.1 Business overview
13.1.16.2 Products offered
13.1.16.3 Recent developments
13.1.16.3.1 Deals
13.1.17 WERFEN, S.A.
13.1.17.1 Business overview
13.1.17.2 Products offered
13.1.17.3 Recent developments
13.1.17.3.1 Deals
13.1.18 QUIDELORTHO CORPORATION
13.1.18.1 Business overview
13.1.18.2 Products offered
13.1.18.3 Recent developments
13.1.18.3.1 Deals
13.1.18.3.2 Expansions
13.1.19 CHEMBIO DIAGNOSTICS, INC.
13.1.19.1 Business overview
13.1.19.2 Products offered
13.1.20 SURMODICS, INC.
13.1.20.1 Business overview
13.1.20.2 Products offered
13.1.21 MERCK KGAA
13.1.21.1 Business overview
13.1.21.2 Products offered
13.2 OTHER PLAYERS
13.2.1 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
13.2.2 CANVAX
13.2.3 PRESTIGE DIAGNOSTICS
13.2.4 ADALTIS S.R.L.
13.2.5 RANDOX LABORATORIES LTD.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
List of Tables
TABLE 1 IVD REAGENTS MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 IVD REAGENTS MARKET: RISK ASSESSMENT
TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION, 2022 VS. 2030 VS. 2050
TABLE 4 RECENT DEVELOPMENTS IN IVD REAGENTS MARKET IN EMERGING ECONOMIES, 2022-2023
TABLE 5 AVERAGE SELLING PRICE TREND OF KEY PLAYERS FOR TOP 2 APPLICATIONS, 2021-2023 (USD)
TABLE 6 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION, 2021-2023 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2021-2023 (USD)
TABLE 8 IVD REAGENTS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 9 IVD REAGENTS MARKET: KEY TECHNOLOGIES
TABLE 10 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 11 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 12 IVD REAGENTS MARKET: KEY CONFERENCES AND EVENTS, 2024-2025
TABLE 13 IVD REAGENTS MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 14 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL FOR IVD REAGENTS
TABLE 15 US: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
TABLE 16 CANADA: CLASSIFICATION OF IVD PRODUCTS
TABLE 17 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
TABLE 18 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES
TABLE 19 EUROPE: CLASSIFICATION OF IVD REAGENTS
TABLE 20 EUROPE: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
TABLE 21 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
TABLE 22 JAPAN: CLASSIFICATION OF IVD REAGENTS
TABLE 23 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 29 GCC COUNTRIES: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD REAGENTS, BY END USER (%)
TABLE 31 KEY BUYING CRITERIA FOR IVD REAGENTS, BY END USER
TABLE 32 IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 33 COMPANIES PROVIDING ANTIBODIES
TABLE 34 ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 35 ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 36 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 37 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 38 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 39 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 40 GCC COUNTRIES: ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 41 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 42 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 43 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 44 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 45 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 46 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 47 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 48 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 49 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 50 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 51 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 52 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 53 COMPANIES PROVIDING ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES
TABLE 54 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 55 NORTH AMERICA: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 56 EUROPE: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 57 ASIA PACIFIC: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 58 LATIN AMERICA: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 59 GCC COUNTRIES: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 60 COMPANIES PROVIDING OLIGONUCLEOTIDES
TABLE 61 OLIGONUCLEOTIDES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 63 EUROPE: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 66 GCC COUNTRIES: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 67 COMPANIES PROVIDING NUCLEIC ACID PROBES
TABLE 68 NUCLEIC ACID PROBES MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 69 NORTH AMERICA: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 70 EUROPE: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 71 ASIA PACIFIC: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 72 LATIN AMERICA: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 73 GCC COUNTRIES: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 74 COMPANIES PROVIDING OTHER IVD REAGENTS
TABLE 75 OTHER IVD REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 76 NORTH AMERICA: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 77 EUROPE: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 78 ASIA PACIFIC: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 79 LATIN AMERICA: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 80 GCC COUNTRIES: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 81 IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 82 IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
TABLE 83 NORTH AMERICA: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 84 EUROPE: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 85 ASIA PACIFIC: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 86 LATIN AMERICA: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 87 GCC COUNTRIES: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 88 IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2022-2029 (USD MILLION)
TABLE 89 NORTH AMERICA: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 90 EUROPE: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 91 ASIA PACIFIC: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 92 LATIN AMERICA: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 93 GCC COUNTRIES: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 94 IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 95 NORTH AMERICA: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 96 EUROPE: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 97 ASIA PACIFIC: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 98 LATIN AMERICA: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 99 GCC COUNTRIES: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 100 IVD REAGENTS MARKET FOR HEMATOLOGY, BY REGION, 2022-2029 (USD MILLION)
TABLE 101 NORTH AMERICA: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 102 EUROPE: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 103 ASIA PACIFIC: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 104 LATIN AMERICA: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 105 GCC COUNTRIES: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 106 IVD REAGENTS MARKET FOR MICROBIOLOGY, BY REGION, 2022-2029 (USD MILLION)
TABLE 107 NORTH AMERICA: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 108 EUROPE: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 109 ASIA PACIFIC: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 110 LATIN AMERICA: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 111 GCC COUNTRIES: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 112 IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 113 NORTH AMERICA: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 114 EUROPE: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 115 ASIA PACIFIC: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 116 LATIN AMERICA: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 117 GCC COUNTRIES: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 118 IVD REAGENTS MARKET FOR URINALYSIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 119 NORTH AMERICA: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 120 EUROPE: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 121 ASIA PACIFIC: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 122 LATIN AMERICA: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 123 GCC COUNTRIES: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 124 IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
TABLE 125 NORTH AMERICA: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 126 EUROPE: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 127 ASIA PACIFIC: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 128 LATIN AMERICA: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 129 GCC COUNTRIES: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 130 IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2022-2029 (USD MILLION)
TABLE 131 NORTH AMERICA: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 132 EUROPE: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 133 ASIA PACIFIC: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 134 LATIN AMERICA: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 135 GCC COUNTRIES: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 136 IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 137 IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
TABLE 138 NORTH AMERICA: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 139 EUROPE: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 140 ASIA PACIFIC: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 141 LATIN AMERICA: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 142 GCC COUNTRIES: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 143 ESTIMATED NUMBER OF NEW CASES OF CANCER FOR 0-85+ YEARS OF AGE, 2022 VS. 2030
TABLE 144 IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 145 NORTH AMERICA: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 146 EUROPE: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 147 ASIA PACIFIC: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 148 LATIN AMERICA: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 149 GCC COUNTRIES: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 150 IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 151 NORTH AMERICA: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 152 EUROPE: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 153 ASIA PACIFIC: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 154 LATIN AMERICA: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 155 GCC COUNTRIES: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 156 IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 157 NORTH AMERICA: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 158 EUROPE: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 159 ASIA PACIFIC: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 160 LATIN AMERICA: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 161 GCC COUNTRIES: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 162 IVD REAGENTS MARKET FOR BLOOD SCREENING, BY REGION, 2022-2029 (USD MILLION)
TABLE 163 NORTH AMERICA: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 164 EUROPE: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 165 ASIA PACIFIC: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 166 LATIN AMERICA: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 167 GCC COUNTRIES: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 168 IVD REAGENTS MARKET FOR GENETIC TESTING, BY REGION, 2022-2029 (USD MILLION)
TABLE 169 NORTH AMERICA: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 170 EUROPE: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 171 ASIA PACIFIC: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 172 LATIN AMERICA: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 173 GCC COUNTRIES: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 174 IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022-2029 (USD MILLION)
TABLE 175 NORTH AMERICA: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 176 EUROPE: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 177 ASIA PACIFIC: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 178 LATIN AMERICA: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 179 GCC COUNTRIES: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 180 IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 181 NORTH AMERICA: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 182 EUROPE: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 183 ASIA PACIFIC: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 184 LATIN AMERICA: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 185 GCC COUNTRIES: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 186 KEY PRODUCTS FOR DRUG MONITORING
TABLE 187 IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2022-2029 (USD MILLION)
TABLE 188 NORTH AMERICA: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 189 EUROPE: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 190 ASIA PACIFIC: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 191 LATIN AMERICA: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 192 GCC COUNTRIES: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 193 IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 194 NORTH AMERICA: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 195 EUROPE: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 196 ASIA PACIFIC: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 197 LATIN AMERICA: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 198 GCC COUNTRIES: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 199 IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 200 IVD REAGENTS MARKET FOR LABORATORY TESTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 201 NORTH AMERICA: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 202 EUROPE: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 203 ASIA PACIFIC: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 204 LATIN AMERICA: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 205 GCC COUNTRIES: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 206 IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 207 NORTH AMERICA: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 208 EUROPE: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 209 ASIA PACIFIC: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 210 LATIN AMERICA: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 211 GCC COUNTRIES: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 212 IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 213 IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 214 NORTH AMERICA: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 215 EUROPE: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 216 ASIA PACIFIC: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 217 LATIN AMERICA: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 218 GCC COUNTRIES: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 219 IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 220 IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 221 NORTH AMERICA: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 222 EUROPE: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 223 ASIA PACIFIC: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 224 LATIN AMERICA: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 225 GCC COUNTRIES: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 226 IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 227 NORTH AMERICA: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 228 EUROPE: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 229 ASIA PACIFIC: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 230 LATIN AMERICA: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 231 GCC COUNTRIES: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 232 IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 233 NORTH AMERICA: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 234 EUROPE: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 235 ASIA PACIFIC: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 236 LATIN AMERICA: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 237 GCC COUNTRIES: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 238 IVD REAGENTS MARKET FOR BLOOD BANKS, BY REGION, 2022-2029 (USD MILLION)
TABLE 239 NORTH AMERICA: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 240 EUROPE: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 241 ASIA PACIFIC: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 242 LATIN AMERICA: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 243 GCC COUNTRIES: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 244 IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2029 (USD MILLION)
TABLE 245 NORTH AMERICA: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 246 EUROPE: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 247 ASIA PACIFIC: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 248 LATIN AMERICA: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 249 GCC COUNTRIES: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 250 IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 251 NORTH AMERICA: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 252 EUROPE: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 253 ASIA PACIFIC: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 254 LATIN AMERICA: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 255 GCC COUNTRIES: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 256 IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
TABLE 257 NORTH AMERICA: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 258 EUROPE: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 259 ASIA PACIFIC: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 260 LATIN AMERICA: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 261 GCC COUNTRIES: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 262 IVD REAGENTS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 263 NORTH AMERICA: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 264 EUROPE: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 265 ASIA PACIFIC: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 266 LATIN AMERICA: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 267 GCC COUNTRIES: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 268 IVD REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 269 KEY IVD REAGENTS PROVIDED BY MAJOR PLAYERS IN NORTH AMERICA
TABLE 270 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 271 NORTH AMERICA: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 272 NORTH AMERICA: IVD TESTS CONDUCTED, BY COUNTRY, 2022-2029 (BILLION UNIT)
TABLE 273 NORTH AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 274 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 275 NORTH AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 276 NORTH AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 277 NORTH AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 278 NORTH AMERICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 279 NORTH AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 280 US: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 281 US: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 282 US: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 283 US: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 284 US: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 285 US: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 286 US: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 287 CANADA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 288 CANADA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 289 CANADA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 290 CANADA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 291 CANADA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 292 CANADA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 293 CANADA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 294 KEY IVD REAGENTS PROVIDED BY MAJOR PLAYERS IN EUROPE
TABLE 295 EUROPE: MACROECONOMIC INDICATORS
TABLE 296 EUROPE: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 297 EUROPE: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 298 EUROPE: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 299 EUROPE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 300 EUROPE: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 301 EUROPE: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 302 EUROPE: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 303 EUROPE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 304 GERMANY: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 305 GERMANY: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 306 GERMANY: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 307 GERMANY: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 308 GERMANY: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 309 GERMANY: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 310 GERMANY: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 311 UK: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 312 UK: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 313 UK: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 314 UK: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 315 UK: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 316 UK: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 317 UK: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 318 FRANCE: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 319 FRANCE: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 320 FRANCE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 321 FRANCE: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 322 FRANCE: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 323 FRANCE: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 324 FRANCE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 325 ITALY: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 326 ITALY: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 327 ITALY: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 328 ITALY: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 329 ITALY: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 330 ITALY: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 331 ITALY: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 332 SPAIN: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 333 SPAIN: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 334 SPAIN: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 335 SPAIN: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 336 SPAIN: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 337 SPAIN: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 338 SPAIN: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 339 REST OF EUROPE: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 340 REST OF EUROPE: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 341 REST OF EUROPE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 342 REST OF EUROPE: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 343 REST OF EUROPE: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 344 REST OF EUROPE: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 345 REST OF EUROPE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 346 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 347 ASIA PACIFIC: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 348 ASIA PACIFIC: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 349 ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 350 ASIA PACIFIC: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 351 ASIA PACIFIC: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 352 ASIA PACIFIC: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 353 ASIA PACIFIC: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 354 ASIA PACIFIC: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 355 JAPAN: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 356 JAPAN: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 357 JAPAN: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 358 JAPAN: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 359 JAPAN: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 360 JAPAN: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 361 JAPAN: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 362 CHINA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 363 CHINA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 364 CHINA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 365 CHINA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 366 CHINA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 367 CHINA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 368 CHINA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 369 INDIA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 370 INDIA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 371 INDIA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 372 INDIA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 373 INDIA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 374 INDIA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 375 INDIA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 376 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 377 REST OF ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 378 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 379 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 380 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 381 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 382 REST OF ASIA PACIFIC: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 383 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 384 LATIN AMERICA: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 385 LATIN AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 386 LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 387 LATIN AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 388 LATIN AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 389 LATIN AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 390 LATIN AMERICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 391 LATIN AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 392 BRAZIL: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 393 BRAZIL: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 394 BRAZIL: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 395 BRAZIL: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 396 BRAZIL: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 397 BRAZIL: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 398 BRAZIL: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 399 MEXICO: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 400 MEXICO: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 401 MEXICO: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 402 MEXICO: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 403 MEXICO: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 404 MEXICO: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 405 MEXICO: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 406 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 407 REST OF LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 408 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 409 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 410 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 411 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 412 REST OF LATIN AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 413 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 414 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 415 MIDDLE EAST & AFRICA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 416 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 417 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 418 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 419 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 420 MIDDLE EAST & AFRICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 421 GCC COUNTRIES: MACROECONOMIC INDICATORS
TABLE 422 GCC COUNTRIES: IVD REAGENTS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 423 GCC COUNTRIES: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 424 GCC COUNTRIES: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 425 GCC COUNTRIES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 426 GCC COUNTRIES: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 427 GCC COUNTRIES: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 428 GCC COUNTRIES: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 429 GCC COUNTRIES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 430 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 431 KINGDOM OF SAUDI ARABIA: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 432 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 433 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 434 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 435 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 436 KINGDOM OF SAUDI ARABIA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 437 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 438 UNITED ARAB EMIRATES: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 439 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 440 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 441 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 442 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 443 UNITED ARAB EMIRATES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 444 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 445 OTHER GCC COUNTRIES: ANTIBODIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 446 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 447 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
TABLE 448 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 449 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 450 OTHER GCC COUNTRIES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 451 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS MARKET, 2021-2023
TABLE 452 IVD REAGENTS MARKET: DEGREE OF COMPETITION
TABLE 453 IVD REAGENTS MARKET: TECHNOLOGY FOOTPRINT
TABLE 454 IVD REAGENTS MARKET: APPLICATION FOOTPRINT
TABLE 455 IVD REAGENTS MARKET: TEST TYPE FOOTPRINT
TABLE 456 IVD REAGENTS MARKET: REGION FOOTPRINT
TABLE 457 IVD REAGENTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 458 IVD REAGENTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 459 IVD REAGENTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-SEPTEMBER 2024
TABLE 460 IVD REAGENTS MARKET: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 461 IVD REAGENTS MARKET: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
TABLE 462 IVD REAGENTS MARKET: OTHER DEVELOPMENTS, JANUARY 2021-SEPTEMBER 2024
TABLE 463 DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 464 DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 465 DANAHER CORPORATION: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 466 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
TABLE 467 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021-SEPTEMBER 2024
TABLE 468 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 469 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 470 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 471 ABBOTT: COMPANY OVERVIEW
TABLE 472 ABBOTT: PRODUCTS OFFERED
TABLE 473 ABBOTT: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 474 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
TABLE 475 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
TABLE 476 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 477 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 478 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 479 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 480 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
TABLE 481 ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 482 ILLUMINA, INC.: PRODUCTS OFFERED
TABLE 483 ILLUMINA, INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 484 BIOMERIEUX: COMPANY OVERVIEW
TABLE 485 BIOMERIEUX: PRODUCTS OFFERED
TABLE 486 BIOMERIEUX: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 487 BD: COMPANY OVERVIEW
TABLE 488 BD: PRODUCTS OFFERED
TABLE 489 BD: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 490 HOLOGIC, INC.: COMPANY OVERVIEW
TABLE 491 HOLOGIC, INC.: PRODUCTS OFFERED
TABLE 492 HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-SEPTEMBER 2024
TABLE 493 HOLOGIC, INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 494 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 495 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
TABLE 496 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 497 SYSMEX CORPORATION: COMPANY OVERVIEW
TABLE 498 SYSMEX CORPORATION: PRODUCTS OFFERED
TABLE 499 SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-SEPTEMBER 2024
TABLE 500 SYSMEX CORPORATION: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 501 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021-SEPTEMBER 2024
TABLE 502 QIAGEN N.V.: COMPANY OVERVIEW
TABLE 503 QIAGEN N.V.: PRODUCTS OFFERED
TABLE 504 QIAGEN N.V.: DEALS, JANUARY 2021-SEPTEMBER 2024
TABLE 505 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 506 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
TABLE 507 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021-SEPTEMBER
